Editas Medicine (EDIT)

$2.46 -0.07 (-2.77%)
Market Cap 247.70M
Revenue (ttm) 40.52M
Net Income (ttm) -160.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -395.01%
Debt to Equity Ratio 0.00
Volume 998,300
Avg Vol 1,460,982
Day's Range N/A - N/A
Shares Out 97.91M
Stochastic %K 5%
Beta 2.14
Analysts Sell
Price Target $5.66

Company Profile

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalasse...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 401 9000
Address:
11 Hurley Street, Cambridge, United States
smokefoeu
smokefoeu May. 16 at 12:46 AM
$EDIT been holding this trash for for way too long long. Wish these guys would just make some F’ing money to spread around wtf….
0 · Reply
Sdwg
Sdwg May. 15 at 8:24 PM
$EDIT clearly no one was impressed after the presentations...not even the primates
1 · Reply
Robert_Dempster
Robert_Dempster May. 15 at 7:30 PM
$EDIT time to load great opportunity one single dose of edit 401 and no more cholesterol pills huge patient population for the treatment so many people taking cholesterol pills like candy this is a game changer.📈🐂
0 · Reply
1GreenDay99RedDays
1GreenDay99RedDays May. 15 at 6:00 PM
$EDIT probably going below $2 this is a 2028’er for takeoff
1 · Reply
Whoami1989
Whoami1989 May. 15 at 3:38 PM
$EDIT this fpos is just so f up
0 · Reply
Sdwg
Sdwg May. 15 at 3:17 PM
$EDIT laughable....
0 · Reply
StockBraker
StockBraker May. 15 at 10:58 AM
$EDIT https://ir.editasmedicine.com/news-releases/news-release-details/editas-medicine-reports-new-preclinical-data-demonstrating
0 · Reply
NinjaXLightning
NinjaXLightning May. 14 at 1:14 PM
$EDIT Launch mode will continue to build through 2026.
0 · Reply
dkm11
dkm11 May. 14 at 11:11 AM
$EDIT
0 · Reply
focafoca99
focafoca99 May. 14 at 10:40 AM
$EDIT demonstrated new preclinical data showing EDIT-401 cut LDL-C by over 90% in primates.
0 · Reply
Latest News on EDIT
Editas Medicine’s EDIT-401 shows efficacy and safety in hyperlipidemia

2026-05-14T10:29:14.000Z - 5 days ago

Editas Medicine’s EDIT-401 shows efficacy and safety in hyperlipidemia

Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting

May 14, 2026, 6:01 AM EDT - 5 days ago

Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting

Editas Medicine reports Q1 EPS (26c), consensus (24c)

2026-05-05T11:49:57.000Z - 14 days ago

Editas Medicine reports Q1 EPS (26c), consensus (24c)

Editas Medicine Announces First Quarter 2026 Results and Business Updates

May 5, 2026, 7:00 AM EDT - 14 days ago

Editas Medicine Announces First Quarter 2026 Results and Business Updates

Editas Medicine Earnings release: Q1 2026

May 5, 2026, 7:00 AM EDT - 14 days ago

Editas Medicine Earnings release: Q1 2026

Editas Medicine Quarterly report: Q1 2026

May 5, 2026, 7:00 AM EDT - 14 days ago

Editas Medicine Quarterly report: Q1 2026

Editas Medicine Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 21 days ago

Editas Medicine Proxy statement: Proxy filing

Editas Medicine Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 21 days ago

Editas Medicine Proxy statement: Proxy filing

Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences

Apr 27, 2026, 4:31 PM EDT - 22 days ago

Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences

Editas Medicine Slides: Corporate presentation

Apr 16, 2026, 7:00 AM EDT - 4 weeks ago

Editas Medicine Slides: Corporate presentation

Editas Medicine price target raised to $15 from $13 at Evercore ISI

2026-04-13T13:45:59.000Z - 5 weeks ago

Editas Medicine price target raised to $15 from $13 at Evercore ISI

Editas Medicine announces USPTO reaffirms prior decision on CRISPR/Cas9 patents

2026-03-27T11:15:12.000Z - 7 weeks ago

Editas Medicine announces USPTO reaffirms prior decision on CRISPR/Cas9 patents

Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference

Mar 27, 2026, 7:00 AM EDT - 7 weeks ago

Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference

Editas Medicine Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 12, 2026, 8:30 AM EDT - 2 months ago

Editas Medicine Transcript: Barclays 28th Annual Global Healthcare Conference

Editas Medicine upgraded to Buy from Hold at JonesResearch

2026-03-10T14:25:34.000Z - 2 months ago

Editas Medicine upgraded to Buy from Hold at JonesResearch

Editas Medicine reports Q4 EPS (6c), consensus (26c)

2026-03-09T11:05:44.000Z - 2 months ago

Editas Medicine reports Q4 EPS (6c), consensus (26c)

Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates

Mar 9, 2026, 7:00 AM EDT - 2 months ago

Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates

Editas Medicine Annual report: Q4 2025

Mar 9, 2026, 7:00 AM EDT - 2 months ago

Editas Medicine Annual report: Q4 2025

Editas Medicine Earnings release: Q4 2025

Mar 9, 2026, 7:00 AM EDT - 2 months ago

Editas Medicine Earnings release: Q4 2025

Editas Medicine Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 10:30 AM EST - 2 months ago

Editas Medicine Transcript: TD Cowen 46th Annual Health Care Conference

Editas Medicine to Participate in Upcoming Investor Conferences

Feb 23, 2026, 9:00 AM EST - 3 months ago

Editas Medicine to Participate in Upcoming Investor Conferences

Genflow Biosciences PLC Announces Directorate Change

Jan 19, 2026, 2:20 AM EST - 4 months ago

Genflow Biosciences PLC Announces Directorate Change

Editas Medicine Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 9:10 AM EST - 6 months ago

Editas Medicine Transcript: Evercore ISI 8th Annual HealthCONx Conference

Editas Medicine price target lowered to $3.50 from $12 at Chardan

2025-11-12T22:30:52.000Z - 6 months ago

Editas Medicine price target lowered to $3.50 from $12 at Chardan

Editas Medicine price target raised to $4.60 from $4 at Clear Street

2025-11-10T21:40:13.000Z - 6 months ago

Editas Medicine price target raised to $4.60 from $4 at Clear Street

Editas Medicine reports Q3 EPS (28c), consensus (38c)

2025-11-10T12:20:51.000Z - 6 months ago

Editas Medicine reports Q3 EPS (28c), consensus (38c)

Editas Medicine Announces Third Quarter 2025 Results and Business Updates

Nov 10, 2025, 7:00 AM EST - 6 months ago

Editas Medicine Announces Third Quarter 2025 Results and Business Updates

Editas Medicine Quarterly report: Q3 2025

Nov 10, 2025, 7:00 AM EST - 6 months ago

Editas Medicine Quarterly report: Q3 2025

Editas Medicine Earnings release: Q3 2025

Nov 10, 2025, 7:00 AM EST - 6 months ago

Editas Medicine Earnings release: Q3 2025

Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025

Nov 3, 2025, 9:00 AM EST - 7 months ago

Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025

Editas Medicine management to meet with Cantor

2025-10-23T19:50:17.000Z - 7 months ago

Editas Medicine management to meet with Cantor

Editas Medicine Transcript: Chardan’s 9th Annual Genetic Medicines Conference

Oct 21, 2025, 8:45 AM EDT - 7 months ago

Editas Medicine Transcript: Chardan’s 9th Annual Genetic Medicines Conference

Editas Medicine Transcript: H. C. Wainwright Genetic Medicines Virtual Conference

Oct 14, 2025, 7:00 AM EDT - 7 months ago

Editas Medicine Transcript: H. C. Wainwright Genetic Medicines Virtual Conference

Editas Medicine reports in vivo preclinical PoC data for EDIT-401

2025-10-09T15:05:11.000Z - 7 months ago

Editas Medicine reports in vivo preclinical PoC data for EDIT-401

Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress

Oct 9, 2025, 11:01 AM EDT - 7 months ago

Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress

Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences

Oct 6, 2025, 9:00 AM EDT - 8 months ago

Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences

Editas Medicine Transcript: Cantor Global Healthcare Conference 2025

Sep 4, 2025, 11:30 AM EDT - 9 months ago

Editas Medicine Transcript: Cantor Global Healthcare Conference 2025

Editas Medicine Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 3, 2025, 8:00 AM EDT - 9 months ago

Editas Medicine Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Editas Medicine Transcript: Status Update

Sep 2, 2025, 8:00 AM EDT - 9 months ago

Editas Medicine Transcript: Status Update

Editas Medicine Press release: Status Update

Sep 2, 2025, 8:00 AM EDT - 9 months ago

Editas Medicine Press release: Status Update

Editas Medicine Slides: Status Update

Sep 2, 2025, 8:00 AM EDT - 9 months ago

Editas Medicine Slides: Status Update

Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate

Sep 2, 2025, 7:00 AM EDT - 9 months ago

Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate

Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate

Aug 28, 2025, 4:01 PM EDT - 9 months ago

Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate

Editas Medicine Announces Second Quarter 2025 Results and Business Updates

Aug 12, 2025, 4:01 PM EDT - 10 months ago

Editas Medicine Announces Second Quarter 2025 Results and Business Updates

Editas Medicine Quarterly report: Q2 2025

Aug 12, 2025, 9:30 AM EDT - 10 months ago

Editas Medicine Quarterly report: Q2 2025

Editas Medicine Earnings release: Q2 2025

Aug 12, 2025, 9:30 AM EDT - 10 months ago

Editas Medicine Earnings release: Q2 2025

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June

Jun 12, 2025, 2:01 AM EDT - 1 year ago

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June

Editas Medicine Slides: Corporate Presentation

May 28, 2025, 7:00 AM EDT - 1 year ago

Editas Medicine Slides: Corporate Presentation

Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June

May 14, 2025, 9:31 AM EDT - 1 year ago

Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June

Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas' Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting

May 14, 2025, 7:01 AM EDT - 1 year ago

Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas' Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting

Editas Medicine Transcript: BofA Securities 2025 Healthcare Conference

May 13, 2025, 8:15 PM EDT - 1 year ago

Editas Medicine Transcript: BofA Securities 2025 Healthcare Conference

Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting

May 13, 2025, 7:01 AM EDT - 1 year ago

Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting

Editas Medicine Announces First Quarter 2025 Results and Business Updates

May 12, 2025, 4:30 PM EDT - 1 year ago

Editas Medicine Announces First Quarter 2025 Results and Business Updates

Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board

May 12, 2025, 4:01 PM EDT - 1 year ago

Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board

Editas Medicine Quarterly report: Q1 2025

May 12, 2025, 9:30 AM EDT - 1 year ago

Editas Medicine Quarterly report: Q1 2025

Editas Medicine Earnings release: Q1 2025

May 12, 2025, 9:30 AM EDT - 1 year ago

Editas Medicine Earnings release: Q1 2025

Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May

May 5, 2025, 4:01 PM EDT - 1 year ago

Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May

Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

Apr 28, 2025, 4:31 PM EDT - 1 year ago

Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

Editas Medicine Proxy statement: Proxy Filing

Apr 15, 2025, 8:00 AM EDT - 1 year ago

Editas Medicine Proxy statement: Proxy Filing

Editas Medicine Proxy statement: Proxy Filing

Apr 15, 2025, 8:00 AM EDT - 1 year ago

Editas Medicine Proxy statement: Proxy Filing

Editas Medicine Slides: Corporate Presentation

Apr 10, 2025, 7:00 AM EDT - 1 year ago

Editas Medicine Slides: Corporate Presentation

Editas Medicine Proxy statement: Proxy Filing

Apr 4, 2025, 8:00 AM EDT - 1 year ago

Editas Medicine Proxy statement: Proxy Filing

Editas Medicine Announces Chief Financial Officer Transition

Mar 20, 2025, 4:01 PM EDT - 1 year ago

Editas Medicine Announces Chief Financial Officer Transition

Editas Medicine Transcript: Barclays 27th Annual Global Healthcare Conference

Mar 11, 2025, 9:00 AM EDT - 1 year ago

Editas Medicine Transcript: Barclays 27th Annual Global Healthcare Conference

Editas Medicine Transcript: Leerink’s Global Healthcare Conference 2025

Mar 10, 2025, 9:20 AM EDT - 1 year ago

Editas Medicine Transcript: Leerink’s Global Healthcare Conference 2025

Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates

Mar 5, 2025, 4:05 PM EST - 1 year ago

Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates

Editas Medicine Annual report: Q4 2024

Mar 5, 2025, 9:30 AM EST - 1 year ago

Editas Medicine Annual report: Q4 2024

Editas Medicine Earnings release: Q4 2024

Mar 5, 2025, 9:30 AM EST - 1 year ago

Editas Medicine Earnings release: Q4 2024

Editas Medicine Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 2:30 PM EST - 1 year ago

Editas Medicine Transcript: TD Cowen 45th Annual Healthcare Conference

Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March

Feb 24, 2025, 9:00 AM EST - 1 year ago

Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March

Editas Medicine Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 2:15 PM EST - 1 year ago

Editas Medicine Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Editas Medicine Slides: Corporate Presentation

Jan 13, 2025, 12:44 PM EST - 1 year ago

Editas Medicine Slides: Corporate Presentation

Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities

Jan 13, 2025, 9:00 AM EST - 1 year ago

Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities

Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 9:00 AM EST - 1 year ago

Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Editas to reduce about 65% of its workforce over the next six months

Dec 12, 2024, 6:03 PM EST - 1 year ago

Editas to reduce about 65% of its workforce over the next six months

Editas Medicine Transcript: Strategy Update

Dec 12, 2024, 5:00 PM EST - 1 year ago

Editas Medicine Transcript: Strategy Update

Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

Dec 12, 2024, 4:00 PM EST - 1 year ago

Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting

Dec 9, 2024, 12:00 PM EST - 1 year ago

Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting

Editas Medicine Transcript: 7th Annual Evercore ISI HealthCONx Conference

Dec 3, 2024, 1:20 PM EST - 1 year ago

Editas Medicine Transcript: 7th Annual Evercore ISI HealthCONx Conference

Editas Medicine Transcript: Stifel 2024 Healthcare Conference

Nov 19, 2024, 1:50 PM EST - 1 year ago

Editas Medicine Transcript: Stifel 2024 Healthcare Conference

Editas Medicine Announces Third Quarter 2024 Results and Business Updates

Nov 4, 2024, 7:30 AM EST - 1 year ago

Editas Medicine Announces Third Quarter 2024 Results and Business Updates

Editas Medicine Quarterly report: Q3 2024

Nov 4, 2024, 7:30 AM EST - 1 year ago

Editas Medicine Quarterly report: Q3 2024

Editas Medicine Earnings release: Q3 2024

Nov 4, 2024, 7:30 AM EST - 1 year ago

Editas Medicine Earnings release: Q3 2024

Editas Medicine Transcript: Strategy Update

Oct 22, 2024, 8:00 AM EDT - 1 year ago

Editas Medicine Transcript: Strategy Update

Editas Medicine Transcript: Strategy Update

Oct 22, 2024, 8:00 AM EDT - 1 year ago

Editas Medicine Transcript: Strategy Update

Editas Medicine Press release: Strategy Update

Oct 22, 2024, 8:00 AM EDT - 1 year ago

Editas Medicine Press release: Strategy Update

Editas Medicine Slides: Strategy Update

Oct 22, 2024, 8:00 AM EDT - 1 year ago

Editas Medicine Slides: Strategy Update

Editas Medicine Slides: Strategy Update

Oct 22, 2024, 8:00 AM EDT - 1 year ago

Editas Medicine Slides: Strategy Update

Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics

Oct 21, 2024, 4:30 PM EDT - 1 year ago

Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics

Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept

Oct 18, 2024, 4:01 PM EDT - 1 year ago

Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept

Editas Medicine (EDIT) Shares Plunge Amid Biotech Sector Fluctuations

Oct 7, 2024, 3:33 PM EDT - 1 year ago

Editas Medicine (EDIT) Shares Plunge Amid Biotech Sector Fluctuations

Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust

Oct 3, 2024, 6:00 PM EDT - 1 year ago

Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust

Editas Medicine Transcript: Chardan Genetic Medicines Conference

Oct 1, 2024, 3:45 PM EDT - 1 year ago

Editas Medicine Transcript: Chardan Genetic Medicines Conference

Editas Medicine Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 17, 2024, 1:20 PM EDT - 1 year ago

Editas Medicine Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Editas Medicine Transcript: 2024 Wells Fargo Healthcare Conference

Sep 5, 2024, 4:30 PM EDT - 1 year ago

Editas Medicine Transcript: 2024 Wells Fargo Healthcare Conference

Editas Medicine Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Sep 4, 2024, 4:05 PM EDT - 1 year ago

Editas Medicine Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Editas Medicine Earnings Call Transcript: Q2 2024

Aug 7, 2024, 8:00 AM EDT - 1 year ago

Editas Medicine Earnings Call Transcript: Q2 2024

Editas Medicine Quarterly report: Q2 2024

Aug 7, 2024, 8:00 AM EDT - 1 year ago

Editas Medicine Quarterly report: Q2 2024

Editas Medicine Earnings release: Q2 2024

Aug 7, 2024, 8:00 AM EDT - 1 year ago

Editas Medicine Earnings release: Q2 2024

Editas Medicine Announces Second Quarter 2024 Results and Business Updates

Aug 7, 2024, 7:00 AM EDT - 1 year ago

Editas Medicine Announces Second Quarter 2024 Results and Business Updates

Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update

Jul 31, 2024, 7:00 AM EDT - 1 year ago

Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update

Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress

Jun 14, 2024, 3:01 AM EDT - 2 years ago

Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress

Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress

Jun 14, 2024, 3:00 AM EDT - 2 years ago

Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress

Editas Medicine Transcript: AGM 2024

May 30, 2024, 8:30 AM EDT - 2 years ago

Editas Medicine Transcript: AGM 2024

Editas Medicine Transcript: RBC Capital Markets 2024 Global Healthcare Conference

May 15, 2024, 2:05 PM EDT - 2 years ago

Editas Medicine Transcript: RBC Capital Markets 2024 Global Healthcare Conference

Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June

May 14, 2024, 10:00 AM EDT - 2 years ago

Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June

Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting

May 10, 2024, 6:00 AM EDT - 2 years ago

Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting

Editas Medicine Earnings Call Transcript: Q1 2024

May 8, 2024, 8:00 AM EDT - 2 years ago

Editas Medicine Earnings Call Transcript: Q1 2024

Editas Medicine Quarterly report: Q1 2024

May 8, 2024, 8:00 AM EDT - 2 years ago

Editas Medicine Quarterly report: Q1 2024

Editas Medicine Earnings release: Q1 2024

May 8, 2024, 8:00 AM EDT - 2 years ago

Editas Medicine Earnings release: Q1 2024

Editas Medicine Announces First Quarter 2024 Results and Business Updates

May 8, 2024, 7:00 AM EDT - 2 years ago

Editas Medicine Announces First Quarter 2024 Results and Business Updates

Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events

May 2, 2024, 7:00 AM EDT - 2 years ago

Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events

Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration

May 1, 2024, 8:00 AM EDT - 2 years ago

Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration

Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

Apr 22, 2024, 4:31 PM EDT - 2 years ago

Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

Editas Medicine Proxy statement: Proxy Filing

Apr 16, 2024, 8:00 AM EDT - 2 years ago

Editas Medicine Proxy statement: Proxy Filing

Editas Medicine Proxy statement: Proxy Filing

Apr 16, 2024, 8:00 AM EDT - 2 years ago

Editas Medicine Proxy statement: Proxy Filing

Editas Medicine Slides: Corporate Presentation

Apr 12, 2024, 6:30 PM EDT - 2 years ago

Editas Medicine Slides: Corporate Presentation

Editas Medicine Transcript: Barclays 26th Annual Global Healthcare Conference 2024

Mar 13, 2024, 2:05 PM EDT - 2 years ago

Editas Medicine Transcript: Barclays 26th Annual Global Healthcare Conference 2024

Editas Medicine Transcript: Leerink Partners Global Biopharma Conference 2024

Mar 12, 2024, 10:40 AM EDT - 2 years ago

Editas Medicine Transcript: Leerink Partners Global Biopharma Conference 2024

Editas Medicine Transcript: TD Cowen 44th Annual Health Care Conference 2024

Mar 4, 2024, 12:50 PM EST - 2 years ago

Editas Medicine Transcript: TD Cowen 44th Annual Health Care Conference 2024

Editas Medicine Earnings Call Transcript: Q4 2023

Feb 28, 2024, 8:00 AM EST - 2 years ago

Editas Medicine Earnings Call Transcript: Q4 2023

Editas Medicine Annual report: Q4 2023

Feb 28, 2024, 8:00 AM EST - 2 years ago

Editas Medicine Annual report: Q4 2023

Editas Medicine Earnings release: Q4 2023

Feb 28, 2024, 8:00 AM EST - 2 years ago

Editas Medicine Earnings release: Q4 2023

Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates

Feb 28, 2024, 7:00 AM EST - 2 years ago

Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates

Editas Medicine Slides: Corporate Presentation

Feb 25, 2024, 1:04 PM EST - 2 years ago

Editas Medicine Slides: Corporate Presentation

Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events

Feb 21, 2024, 7:00 AM EST - 2 years ago

Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events

Editas Medicine Transcript: Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 13, 2024, 8:40 AM EST - 2 years ago

Editas Medicine Transcript: Oppenheimer 34th Annual Healthcare Life Sciences Conference

Editas Medicine Transcript: Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

Feb 7, 2024, 9:30 AM EST - 2 years ago

Editas Medicine Transcript: Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

Editas Medicine Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Jan 9, 2024, 7:30 PM EST - 2 years ago

Editas Medicine Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference

Jan 8, 2024, 8:15 AM EST - 2 years ago

Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference

Editas Medicine Slides: Corporate Presentation

Jan 5, 2024, 7:00 AM EST - 2 years ago

Editas Medicine Slides: Corporate Presentation

Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 3, 2024, 7:00 AM EST - 2 years ago

Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference

2 gene-editing stocks reshaping hereditary disease treatments

Jan 2, 2024, 7:16 AM EST - 2 years ago

2 gene-editing stocks reshaping hereditary disease treatments

NTLA

smokefoeu
smokefoeu May. 16 at 12:46 AM
$EDIT been holding this trash for for way too long long. Wish these guys would just make some F’ing money to spread around wtf….
0 · Reply
Sdwg
Sdwg May. 15 at 8:24 PM
$EDIT clearly no one was impressed after the presentations...not even the primates
1 · Reply
Robert_Dempster
Robert_Dempster May. 15 at 7:30 PM
$EDIT time to load great opportunity one single dose of edit 401 and no more cholesterol pills huge patient population for the treatment so many people taking cholesterol pills like candy this is a game changer.📈🐂
0 · Reply
1GreenDay99RedDays
1GreenDay99RedDays May. 15 at 6:00 PM
$EDIT probably going below $2 this is a 2028’er for takeoff
1 · Reply
Whoami1989
Whoami1989 May. 15 at 3:38 PM
$EDIT this fpos is just so f up
0 · Reply
Sdwg
Sdwg May. 15 at 3:17 PM
$EDIT laughable....
0 · Reply
StockBraker
StockBraker May. 15 at 10:58 AM
$EDIT https://ir.editasmedicine.com/news-releases/news-release-details/editas-medicine-reports-new-preclinical-data-demonstrating
0 · Reply
NinjaXLightning
NinjaXLightning May. 14 at 1:14 PM
$EDIT Launch mode will continue to build through 2026.
0 · Reply
dkm11
dkm11 May. 14 at 11:11 AM
$EDIT
0 · Reply
focafoca99
focafoca99 May. 14 at 10:40 AM
$EDIT demonstrated new preclinical data showing EDIT-401 cut LDL-C by over 90% in primates.
0 · Reply
focafoca99
focafoca99 May. 14 at 10:14 AM
$EDIT presented new preclinical data showing EDIT-401 achieved over 90% LDL‑C reduction in primates, highlighting a potential one‑time
0 · Reply
Sdwg
Sdwg May. 13 at 10:50 PM
$EDIT hmmm, the presentations do t seem to be impressing anyone enough for them to buy shares....glta
0 · Reply
Whoami1989
Whoami1989 May. 13 at 4:19 PM
$EDIT is fpos. no one cares to invest
0 · Reply
0x126
0x126 May. 13 at 8:43 AM
$EDIT a woopsy, +9% pre-market?
0 · Reply
RedTop1
RedTop1 May. 11 at 2:20 PM
$EDIT Just need a little PR to get this jumping. Been accumulating in the 1000's of shrs!
1 · Reply
BillionerOfKing
BillionerOfKing May. 11 at 1:34 PM
$EDIT Current Stock Price: $3.21 Contracts to trade: $2.5 EDIT May 15 2026 Call Entry: $0.60 Exit: $0.81 ROI: 35% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
svertical1
svertical1 May. 9 at 5:20 AM
$CRSP Should be CRSP, $EDIT $NTLA https://x.com/agingroy/status/2052840682662793528?s=42&t=lVKGgcMdQmE679bIABPvLg
0 · Reply
Jami_JO
Jami_JO May. 8 at 5:15 PM
$EDIT $NTLA $CRSP
0 · Reply
NewEarth
NewEarth May. 8 at 2:34 PM
$NTLA $BEAM $EDIT $REGN $PRME Jennifer and Intellia are going to hold the market of all these treatments
0 · Reply
RocroBio
RocroBio May. 7 at 5:40 PM
$BEAM $CRBU $EDIT $NTLA
0 · Reply
Sdwg
Sdwg May. 7 at 3:46 PM
$EDIT would be a miracle if some insiders would buy a few shares....must have option grants up the wazzoo...no mention of future licensing royalties in earning release...kind of a fail on managements part, no?
0 · Reply
harryvanluik
harryvanluik May. 5 at 2:14 PM
$EDIT https://finance.yahoo.com/sectors/healthcare/articles/editas-medicine-announces-first-quarter-110000665.html nothing really new, just confirmation that we are definitely sitting on the right flight to heaven.
0 · Reply